SG11202002968UA - Compound having erk kinase inhibitory activity and use thereof - Google Patents
Compound having erk kinase inhibitory activity and use thereofInfo
- Publication number
- SG11202002968UA SG11202002968UA SG11202002968UA SG11202002968UA SG11202002968UA SG 11202002968U A SG11202002968U A SG 11202002968UA SG 11202002968U A SG11202002968U A SG 11202002968UA SG 11202002968U A SG11202002968U A SG 11202002968UA SG 11202002968U A SG11202002968U A SG 11202002968UA
- Authority
- SG
- Singapore
- Prior art keywords
- compound
- inhibitory activity
- kinase inhibitory
- erk kinase
- erk
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710915493 | 2017-09-30 | ||
| PCT/CN2018/108762 WO2019062949A1 (en) | 2017-09-30 | 2018-09-29 | Compound having erk kinase inhibitory activity and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002968UA true SG11202002968UA (en) | 2020-04-29 |
Family
ID=65902341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002968UA SG11202002968UA (en) | 2017-09-30 | 2018-09-29 | Compound having erk kinase inhibitory activity and use thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11465984B2 (en) |
| EP (1) | EP3702354B1 (en) |
| JP (1) | JP7216105B2 (en) |
| KR (1) | KR20200078510A (en) |
| CN (1) | CN109863147A (en) |
| AU (1) | AU2018339722B2 (en) |
| BR (1) | BR112020006294A2 (en) |
| CA (1) | CA3080623C (en) |
| EA (1) | EA202090888A1 (en) |
| IL (1) | IL273655B2 (en) |
| MX (1) | MX2020003240A (en) |
| NZ (1) | NZ763197A (en) |
| SG (1) | SG11202002968UA (en) |
| WO (1) | WO2019062949A1 (en) |
| ZA (1) | ZA202001823B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023080193A1 (en) * | 2021-11-04 | 2023-05-11 | 日産化学株式会社 | Method for producing indole compound |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106928216A (en) * | 2015-12-31 | 2017-07-07 | 中国科学院上海药物研究所 | Compound, Preparation Method And The Use with ERK kinase inhibiting activities |
| ES2776658T3 (en) * | 2016-01-22 | 2020-07-31 | Janssen Pharmaceutica Nv | New 6-membered heteroaromatic substituent cyanoindoline derivatives as NIK inhibitors |
| HUE047684T2 (en) * | 2016-01-22 | 2020-05-28 | Janssen Pharmaceutica Nv | New substituted cyanoindoline derivatives as nik inhibitors |
-
2018
- 2018-09-29 US US16/652,148 patent/US11465984B2/en active Active
- 2018-09-29 WO PCT/CN2018/108762 patent/WO2019062949A1/en active Application Filing
- 2018-09-29 JP JP2020539131A patent/JP7216105B2/en active Active
- 2018-09-29 EP EP18862819.2A patent/EP3702354B1/en active Active
- 2018-09-29 KR KR1020207012147A patent/KR20200078510A/en not_active Application Discontinuation
- 2018-09-29 AU AU2018339722A patent/AU2018339722B2/en active Active
- 2018-09-29 BR BR112020006294-4A patent/BR112020006294A2/en unknown
- 2018-09-29 MX MX2020003240A patent/MX2020003240A/en unknown
- 2018-09-29 CA CA3080623A patent/CA3080623C/en active Active
- 2018-09-29 IL IL273655A patent/IL273655B2/en unknown
- 2018-09-29 CN CN201880001907.6A patent/CN109863147A/en active Pending
- 2018-09-29 NZ NZ763197A patent/NZ763197A/en unknown
- 2018-09-29 SG SG11202002968UA patent/SG11202002968UA/en unknown
- 2018-09-29 EA EA202090888A patent/EA202090888A1/en unknown
-
2020
- 2020-03-23 ZA ZA2020/01823A patent/ZA202001823B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3702354B1 (en) | 2024-05-22 |
| IL273655A (en) | 2020-05-31 |
| EP3702354A4 (en) | 2021-02-24 |
| BR112020006294A2 (en) | 2020-10-06 |
| JP2020536120A (en) | 2020-12-10 |
| AU2018339722A1 (en) | 2020-04-23 |
| JP7216105B2 (en) | 2023-01-31 |
| EA202090888A1 (en) | 2021-01-27 |
| EP3702354A1 (en) | 2020-09-02 |
| IL273655B2 (en) | 2023-09-01 |
| US11465984B2 (en) | 2022-10-11 |
| NZ763197A (en) | 2024-03-22 |
| US20200247781A1 (en) | 2020-08-06 |
| IL273655B1 (en) | 2023-05-01 |
| WO2019062949A1 (en) | 2019-04-04 |
| CN109863147A (en) | 2019-06-07 |
| CA3080623A1 (en) | 2019-04-04 |
| KR20200078510A (en) | 2020-07-01 |
| ZA202001823B (en) | 2022-10-26 |
| MX2020003240A (en) | 2020-11-24 |
| CA3080623C (en) | 2023-10-10 |
| AU2018339722B2 (en) | 2022-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202001340B (en) | Heterocyclic compound and use thereof | |
| IL271999A (en) | Tyk2 inhibitors and uses thereof | |
| EP3486244A4 (en) | New compound having fgfr inhibitory activity and preparation and application thereof | |
| EP3620456A4 (en) | Compound with kinase inhibitory activity and preparation method and use thereof | |
| EP3337375A4 (en) | Rack and dishwasher including the same | |
| SG10201913927VA (en) | Kinase inhibitors and uses thereof | |
| PL3621694T3 (en) | Lrrc33 inhibitors and use thereof | |
| EP3337376A4 (en) | Rack and dishwasher including the same | |
| EP3555051A4 (en) | Heparanase inhibitors and use thereof | |
| IL280644A (en) | Magnesium-serinate compound and use thereof | |
| KR102135648B9 (en) | Leoidin compound having anti-virulence activity and use thereof | |
| EP3564242A4 (en) | Compound for selectively inhibiting kinase and use thereof | |
| SG11202012241RA (en) | Erk inhibitor and use thereof | |
| EP3409668A4 (en) | Novel imidazole derivative having jnk inhibitory activity and use thereof | |
| IL273655A (en) | Compound having erk kinase inhibitory activity and use thereof | |
| EP3246314A4 (en) | Carbamate compound and use thereof | |
| EP3246312A4 (en) | Carbamate compound and use thereof | |
| EP3246319A4 (en) | Carbamate compound and use thereof | |
| IL258370A (en) | Oxa-diazaspiro compounds having activity against pain | |
| IL283106A (en) | Erk inhibitors and uses thereof | |
| EP3246316A4 (en) | Carbamate compound and use thereof | |
| EP3246318A4 (en) | Carbamate compound and use thereof | |
| HK1255248A1 (en) | Amide derivatives having multimodal activity against pain | |
| EP3607339A4 (en) | Activity mri | |
| EP3555071A4 (en) | Heparanase inhibitors and use thereof |